Managing adverse effects of cutaneous T-cell lymphoma treatment with supportive care measures

Autor:	Larisa J. Geskin, Sara K. Story
Rok vydání:	2013
Předmět:	Bexarotene medicine.medical_specialty business.industry Cutaneous T-cell lymphoma Pralatrexate Dermatology medicine.disease Romidepsin Clinical trial New medications Immunology Medicine business Brentuximab vedotin Intensive care medicine Adverse effect medicine.drug
Zdroj:	Expert Review of Dermatology. 8:335-338
ISSN:	1746-9880 1746-9872
DOI:	10.1586/17469872.2013.814902
Popis:	Over the last 15 years, the number of therapies for CTCL has grown rapidly and continues to do so as new medications are enter-ing clinical trials and seeking US FDA approval. Adverse events (AEs) related to a new therapy sometimes become the treatment-limiting factor. Fortunately, AEs for many medications can be suc-cessfully managed, allowing for contin-ued use and benefit from therapy. Here, we discuss the management of common AEs of several topical and systemic medi -cations frequently used in the treatment of CTCL.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8ba5b001f72c6aa51eb16a44fc8bc0c6 https://doi.org/10.1586/17469872.2013.814902 Zobrazit plný text záznamu